B
Bull
Bull · 25%HLVX
$2.37
Szenariopreis
$2.090
-0.010 (-0.48%)Zum Schluss
Loading chart…
- High
- 2.110
- Open
- 2.100
- VWAP
- 2.10
- Vol
- 2.80M
- Mkt Cap
- 664.77M
- Low
- 2.090
- Amount
- 5.87M
- EV/EBITDA, TTM
- 0.76
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The Company has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Bewertungskennzahlen
The current forward P/E ratio for Hillevax Inc (HLVX) is -0.87, compared to its 5-year average forward P/E of -3.34.
Alphio AI Price Scenarios for HLVX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.509-17GlobenewswireXOMA Royalty Completes Tender Offer for HilleVax, Inc.
7.008-20PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, HLVX, AVDX on Behalf of Shareholders
7.008-19GlobenewswireHILLEVAX INVESTOR NOTICE FROM FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Examines Price and Process Sufficiency in HilleVax, Inc. Sale Proposal - HLVX
7.008-12PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, HLVX, AMWD on Behalf of Shareholders
7.008-08PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders
HLVX FAQ — answered by Alphio AI
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The Company has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.